Skip to main contentSkip to navigation
Sirius Investors
Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
NASDAQHealthcare

Orchard Therapeutics plc (ORTX) Investment Research Dashboard

About Orchard Therapeutics plc (ORTX) stock analysis

Get live ORTX stock price $16.70, comprehensive Orchard Therapeutics plc stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ORTX stock data and investment insights.

16.70
0.30%Today
Market Cap
380.11M
Volume
372.35K
52W High
16.72
52W Low
4.24

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy s...

Company Information

CEO
Hubert Baburaj Gaspar
Sector
Healthcare
Industry
Biotechnology
Employees
166

Contact Information

Address
108 Cannon Street
Country
GB

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.55) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Orchard Therapeutics plc shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Orchard Therapeutics plc
  • Investors should consider how Orchard Therapeutics plc fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

380.11M

P/E Ratio (TTM)

-4.07

Beta

0.55

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.7
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.5%29.2
43/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
37/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.